Forian reveals it has received an unsolicited proposal to go private at $2.10 per share.
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 25 2025
0mins
Should l Buy FORA?
Proposal for Going Private: Forian's board received an unsolicited proposal from founder Max Wygod and others to take the company private at $2.10 per share.
Ownership Stake: Wygod and other participants in the proposal own about 63% of Forian's common stock.
Special Committee Formation: A Special Committee of independent directors has been established to evaluate the proposal and determine the next steps.
Conditions for Proposal: The proposal is contingent on financing, satisfactory agreements, and approval from the Special Committee, with no guarantee of a definitive offer or agreement.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy FORA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on FORA
Wall Street analysts forecast FORA stock price to fall
1 Analyst Rating
0 Buy
1 Hold
0 Sell
Hold
Current: 2.150
Low
2.10
Averages
2.10
High
2.10
Current: 2.150
Low
2.10
Averages
2.10
High
2.10
About FORA
Forian Inc. is a healthtech company. It is a provider of data science-driven information and analytics solutions to the life science, healthcare and financial services industries. It provides a suite of data management capabilities and proprietary information and analytics solutions to optimize and measure the operational, clinical and financial performance of customers within the healthcare and life sciences and financial services industries. It has expertise in acquiring, integrating, normalizing and commercializing large-scale healthcare data assets. Its solutions include CHRONOS, Chartis, real-world evidence (RWE) and Kyber Data Science. CHRONOS combines open and closed claims, electronic health records, and social determinants of health data into a single, integrated model. It also provides researchers access to healthcare payers, providers, and clinical data with non-traditional healthcare sources, such as social determinants of health (SDoH) data, to uncover novel insights.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Investor Rights Law Firm Investigates Multiple Companies
- Investigation Focus: Halper Sadeh LLC is investigating Avanos Medical, Inc. (NYSE: AVNS) for potential violations of federal securities laws related to its sale to American Industrial Partners for $25.00 per share in cash, raising concerns about fiduciary duties to shareholders.
- Shareholder Rights: Leggett & Platt, Incorporated (NYSE: LEG) is set to sell to Somnigroup International Inc. for 0.1455 shares of Somnigroup common stock per Leggett share, resulting in Leggett shareholders owning approximately 9% of the combined entity, with Halper Sadeh LLC encouraging shareholders to explore their rights and options.
- Cash Transaction: Soleno Therapeutics, Inc. (NASDAQ: SLNO) plans to sell to Neurocrine Biosciences for $53.00 per share in cash, prompting Halper Sadeh LLC to remind shareholders of their potential legal rights.
- Management Involvement: Forian Inc. (NASDAQ: FORA) is being sold for $2.17 per share in cash to a consortium led by CEO Max Wygod, with Halper Sadeh LLC potentially seeking increased consideration and other remedies to protect shareholder interests.
See More
Investigations into Multiple Medical Company Mergers
- Avanos Medical Acquisition: Avanos Medical is set to be acquired by American Industrial Partners for $25.00 per share in an all-cash deal valued at approximately $1.272 billion, with investigations focusing on whether the board breached fiduciary duties by failing to ensure a fair process for shareholders.
- Leggett & Platt Merger: Leggett & Platt will be acquired by Somnigroup International in an all-stock transaction valued at around $2.5 billion, where shareholders will receive 0.1455 shares of Somnigroup for each share of Leggett & Platt, raising concerns about potential fiduciary breaches by the board.
- Soleno Therapeutics Acquisition: Soleno is to be acquired by Neurocrine Biosciences for $53.00 per share in cash, representing a total equity value of approximately $2.9 billion, with investigations questioning the fairness of the deal given it is below the company's 52-week high of $90.32.
- Forian, Inc. Investigation: Forian will be acquired by an entity affiliated with CEO Max Wygod for $2.17 per share in cash, with investigations looking into whether the board failed to conduct a fair process, potentially impacting shareholder value.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Investigation Focus: Halper Sadeh LLC is investigating companies such as Globalstar, Inc., Apellis Pharmaceuticals, Inc., and Forian Inc. for potential violations of federal securities laws and breaches of fiduciary duties, which may impact shareholder rights.
- Transaction Details: Globalstar is being sold for $90 per share in cash or 0.3210 shares of Amazon stock, Apellis for $41 per share in cash plus two contingent value rights of $2 each, and Forian for $2.17 per share in cash, indicating varied transaction structures and associated risks.
- Shareholder Rights Protection: The firm encourages shareholders to contact them to discuss their rights and options at no upfront cost, aiming to provide legal support for affected shareholders and ensure their interests are represented.
- Legal Implications: The firm may seek increased consideration, additional disclosures, or other relief measures to protect shareholder rights, reflecting a commitment to corporate governance and transparency.
See More
Investor Rights Law Firm Investigates Multiple Companies for Potential Violations
- Legal Investigation Launched: Halper Sadeh LLC is investigating Soleno Therapeutics, Inc. (NASDAQ: SLNO) regarding its sale to Neurocrine Biosciences for $53.00 per share, as potential violations of shareholder rights may exist, prompting investors to be aware of their rights and options.
- Acquisition Deal Scrutiny: Forian Inc. (NASDAQ: FORA) is being acquired by a consortium of investors for $2.17 per share, and Halper Sadeh LLC advises shareholders to pay attention to their legal rights to ensure transparency and fairness in the transaction.
- Merger Transaction Impact: The merger between McCormick & Company, Incorporated (NYSE: MKC) and Unilever’s Foods business will result in McCormick shareholders owning 35.0% of the combined entity, with Halper Sadeh LLC potentially seeking increased compensation and disclosures for shareholders.
- Shareholder Rights Protection: Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) is merging with Korsana Biosciences, which is expected to give Cyclerion shareholders approximately 1.5% ownership in the combined company, and Halper Sadeh LLC will represent shareholders in seeking legal remedies and rights protection.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Legal Investigation Launched: Halper Sadeh LLC is investigating Soleno Therapeutics, Inc. (NASDAQ:SLNO) regarding its sale to Neurocrine Biosciences for $53.00 per share in cash, which may infringe on shareholder rights.
- Shareholder Rights Protection: Forian Inc. (NASDAQ:FORA) is being acquired by a consortium for $2.17 per share, prompting Halper Sadeh LLC to remind shareholders to consider their legal rights and options.
- Acquisition Terms Review: Affinity Bancshares, Inc. (NASDAQ:AFBI) is selling to Fidelity BancShares (N.C.) for $23.00 per share, with terms subject to adjustment based on adjusted stockholders' equity, necessitating shareholder awareness of potential impacts on their rights.
- Merger Transaction Impact: McCormick & Company, Incorporated (NYSE:MKC) is merging with Unilever's Foods business, resulting in McCormick shareholders owning 35.0% of the combined entity, with Halper Sadeh LLC potentially seeking increased compensation and disclosures for shareholders.
See More
Investigation Alerts for Multiple Company Mergers
- Soleno Acquisition Investigation: Soleno Therapeutics is set to be acquired by Neurocrine Biosciences for $53.00 per share, totaling approximately $2.9 billion, yet this price is below its 52-week high of $90.32, raising concerns among investors about the board's fiduciary duties.
- Affinity Bancshares Merger Review: Affinity Bancshares will be acquired by Fidelity BancShares for $23.00 per share, with a total transaction value of about $142.8 million, as investigations question whether the board conducted a fair process, potentially impacting shareholder rights.
- Forian Acquisition Scrutiny: Forian will be acquired by an entity affiliated with CEO Max Wygod for $2.17 per share, with investigations focusing on whether the board failed to uphold fiduciary duties, affecting shareholder confidence in the deal.
- Janus Henderson Acquisition Investigation: Janus Henderson is to be acquired by Trian and General Catalyst for $49.00 per share, amounting to approximately $7.4 billion, with investigations examining whether the board ensured fair value for shareholders, which could jeopardize shareholder interests.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Investigation Focus: Halper Sadeh LLC is investigating Avanos Medical, Inc. (NYSE: AVNS) for potential violations of federal securities laws related to its sale to American Industrial Partners for $25.00 per share in cash, raising concerns about fiduciary duties to shareholders.
- Shareholder Rights: Leggett & Platt, Incorporated (NYSE: LEG) is set to sell to Somnigroup International Inc. for 0.1455 shares of Somnigroup common stock per Leggett share, resulting in Leggett shareholders owning approximately 9% of the combined entity, with Halper Sadeh LLC encouraging shareholders to explore their rights and options.
- Cash Transaction: Soleno Therapeutics, Inc. (NASDAQ: SLNO) plans to sell to Neurocrine Biosciences for $53.00 per share in cash, prompting Halper Sadeh LLC to remind shareholders of their potential legal rights.
- Management Involvement: Forian Inc. (NASDAQ: FORA) is being sold for $2.17 per share in cash to a consortium led by CEO Max Wygod, with Halper Sadeh LLC potentially seeking increased consideration and other remedies to protect shareholder interests.
See More
Investigations into Multiple Medical Company Mergers
- Avanos Medical Acquisition: Avanos Medical is set to be acquired by American Industrial Partners for $25.00 per share in an all-cash deal valued at approximately $1.272 billion, with investigations focusing on whether the board breached fiduciary duties by failing to ensure a fair process for shareholders.
- Leggett & Platt Merger: Leggett & Platt will be acquired by Somnigroup International in an all-stock transaction valued at around $2.5 billion, where shareholders will receive 0.1455 shares of Somnigroup for each share of Leggett & Platt, raising concerns about potential fiduciary breaches by the board.
- Soleno Therapeutics Acquisition: Soleno is to be acquired by Neurocrine Biosciences for $53.00 per share in cash, representing a total equity value of approximately $2.9 billion, with investigations questioning the fairness of the deal given it is below the company's 52-week high of $90.32.
- Forian, Inc. Investigation: Forian will be acquired by an entity affiliated with CEO Max Wygod for $2.17 per share in cash, with investigations looking into whether the board failed to conduct a fair process, potentially impacting shareholder value.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Investigation Focus: Halper Sadeh LLC is investigating companies such as Globalstar, Inc., Apellis Pharmaceuticals, Inc., and Forian Inc. for potential violations of federal securities laws and breaches of fiduciary duties, which may impact shareholder rights.
- Transaction Details: Globalstar is being sold for $90 per share in cash or 0.3210 shares of Amazon stock, Apellis for $41 per share in cash plus two contingent value rights of $2 each, and Forian for $2.17 per share in cash, indicating varied transaction structures and associated risks.
- Shareholder Rights Protection: The firm encourages shareholders to contact them to discuss their rights and options at no upfront cost, aiming to provide legal support for affected shareholders and ensure their interests are represented.
- Legal Implications: The firm may seek increased consideration, additional disclosures, or other relief measures to protect shareholder rights, reflecting a commitment to corporate governance and transparency.
See More
Investor Rights Law Firm Investigates Multiple Companies for Potential Violations
- Legal Investigation Launched: Halper Sadeh LLC is investigating Soleno Therapeutics, Inc. (NASDAQ: SLNO) regarding its sale to Neurocrine Biosciences for $53.00 per share, as potential violations of shareholder rights may exist, prompting investors to be aware of their rights and options.
- Acquisition Deal Scrutiny: Forian Inc. (NASDAQ: FORA) is being acquired by a consortium of investors for $2.17 per share, and Halper Sadeh LLC advises shareholders to pay attention to their legal rights to ensure transparency and fairness in the transaction.
- Merger Transaction Impact: The merger between McCormick & Company, Incorporated (NYSE: MKC) and Unilever’s Foods business will result in McCormick shareholders owning 35.0% of the combined entity, with Halper Sadeh LLC potentially seeking increased compensation and disclosures for shareholders.
- Shareholder Rights Protection: Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) is merging with Korsana Biosciences, which is expected to give Cyclerion shareholders approximately 1.5% ownership in the combined company, and Halper Sadeh LLC will represent shareholders in seeking legal remedies and rights protection.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Legal Investigation Launched: Halper Sadeh LLC is investigating Soleno Therapeutics, Inc. (NASDAQ:SLNO) regarding its sale to Neurocrine Biosciences for $53.00 per share in cash, which may infringe on shareholder rights.
- Shareholder Rights Protection: Forian Inc. (NASDAQ:FORA) is being acquired by a consortium for $2.17 per share, prompting Halper Sadeh LLC to remind shareholders to consider their legal rights and options.
- Acquisition Terms Review: Affinity Bancshares, Inc. (NASDAQ:AFBI) is selling to Fidelity BancShares (N.C.) for $23.00 per share, with terms subject to adjustment based on adjusted stockholders' equity, necessitating shareholder awareness of potential impacts on their rights.
- Merger Transaction Impact: McCormick & Company, Incorporated (NYSE:MKC) is merging with Unilever's Foods business, resulting in McCormick shareholders owning 35.0% of the combined entity, with Halper Sadeh LLC potentially seeking increased compensation and disclosures for shareholders.
See More
Investigation Alerts for Multiple Company Mergers
- Soleno Acquisition Investigation: Soleno Therapeutics is set to be acquired by Neurocrine Biosciences for $53.00 per share, totaling approximately $2.9 billion, yet this price is below its 52-week high of $90.32, raising concerns among investors about the board's fiduciary duties.
- Affinity Bancshares Merger Review: Affinity Bancshares will be acquired by Fidelity BancShares for $23.00 per share, with a total transaction value of about $142.8 million, as investigations question whether the board conducted a fair process, potentially impacting shareholder rights.
- Forian Acquisition Scrutiny: Forian will be acquired by an entity affiliated with CEO Max Wygod for $2.17 per share, with investigations focusing on whether the board failed to uphold fiduciary duties, affecting shareholder confidence in the deal.
- Janus Henderson Acquisition Investigation: Janus Henderson is to be acquired by Trian and General Catalyst for $49.00 per share, amounting to approximately $7.4 billion, with investigations examining whether the board ensured fair value for shareholders, which could jeopardize shareholder interests.
See More
